CARLSBAD, Calif., June 17, 2013 /PRNewswire/ -- Life Technologies Corporation (NASDAQ: LIFE) today announced the launch of Epi5™ Episomal iPSC Reprogramming Vectors, the world's first product to be fully commercialized based on technology that won its developers a Nobel Prize in 2012 for the ability to easily reprogram adult human cells into an early embryonic state.
Scientists use induced pluripotent stem cell (iPSC) technology to create iPSCs from patient-derived adult somatic cells. The iPSCs can then be differentiated into many cell types, such as neurons and hepatocytes, to be studied in the lab. The ease-of-use and reprogramming efficiency of Epi5™ Episomal iPSC Reprogramming Vectors helps accelerate the process for applications in basic research and pre-clinical studies.
"You can give rise to iPSCs at a high efficiency rate by using the Epi5 ™ Episomal iPSC Reprogramming Kit," said Dr. Keisuke Okita, Lecturer, Center for iPS Cell Research and Application, Kyoto University, who helped developed the Nobel Prize-winning technology with Dr. Shinya Yamanaka. "We are delighted to see that Life Technologies is taking the lead to make it available and we hope that many researchers will use it to advance research in areas such as pathology, drug discovery and stem cell biology."
While other reprogramming vectors have been developed in Dr. Yamanaka's lab, none has ever been commercially available. Epi5™ Episomal iPSC Reprogramming Vectors is the result of a global, non-exclusive license agreement Life Technologies signed last year with iPS Academia Japan for its iPSC patent portfolio. The license expands Life's range of products and services and underscores the company's commitment to provide the most innovative tools to the iPSC community."The ability to easily generate iPS cells from patient-derived adult somatic cells allows researchers to study the genetics behind specific diseases," said Chris Armstrong, Ph.D., General Manager and Vice President of Primary and Stem Cell Systems at Life Technologies. "This is a crucial step toward development of new potential treatments and one that we are committed to supporting with leading technologies." Epi5™ Episomal iPSC Reprogramming Vectors is For Research Use Only, not intended for diagnostic purposes.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV